Compare WEN & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEN | NVCR |
|---|---|---|
| Founded | 1969 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | WEN | NVCR |
|---|---|---|
| Price | $8.66 | $14.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 21 | 6 |
| Target Price | $10.11 | ★ $28.42 |
| AVG Volume (30 Days) | ★ 5.6M | 1.3M |
| Earning Date | 02-12-2026 | 02-26-2026 |
| Dividend Yield | ★ 6.47% | N/A |
| EPS Growth | ★ 0.63 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $2,208,190,000.00 | $642,269,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | $3.06 | $5.62 |
| P/E Ratio | $9.15 | ★ N/A |
| Revenue Growth | N/A | ★ 11.17 |
| 52 Week Low | $7.83 | $10.70 |
| 52 Week High | $16.20 | $28.56 |
| Indicator | WEN | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 57.21 | 62.61 |
| Support Level | $8.08 | $14.13 |
| Resistance Level | $8.50 | $13.64 |
| Average True Range (ATR) | 0.24 | 0.53 |
| MACD | 0.04 | 0.14 |
| Stochastic Oscillator | 88.46 | 69.80 |
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $12.6 billion in 2024, narrowly edging Burger King ($11.5 billion) and clocking in well behind wide-moat McDonald's ($51.1 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spanned more than 7,200 total stores in 30 countries as of year-end 2024. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for roughly 94% of stores, and through franchise flipping and advisory fees.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.